Complex roles of cAMP–PKA–CREB signaling in cancer
H Zhang, Q Kong, J Wang, Y Jiang, H Hua - Experimental hematology & …, 2020 - Springer
Cyclic adenosine monophosphate (cAMP) is the first discovered second messenger, which
plays pivotal roles in cell signaling, and regulates many physiological and pathological …
plays pivotal roles in cell signaling, and regulates many physiological and pathological …
Cancer, metastasis, and the epigenome
S Kiri, T Ryba - Molecular Cancer, 2024 - Springer
Cancer is the second leading cause of death worldwide and disease burden is expected to
increase globally throughout the next several decades, with the majority of cancer-related …
increase globally throughout the next several decades, with the majority of cancer-related …
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Abstract The AURORA US Metastasis Project was established with the goal to identify
molecular features associated with metastasis. We assayed 55 females with metastatic …
molecular features associated with metastasis. We assayed 55 females with metastatic …
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Background About 50% of all primary breast cancers show a low-level expression of HER2
(HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene …
(HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene …
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
Constitutively active estrogen receptor α (ER/ESR1) mutations have been identified in
approximately one-third of ER+ metastatic breast cancers. Although these mutations are …
approximately one-third of ER+ metastatic breast cancers. Although these mutations are …
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
MT Herrera-Abreu, J Guan, U Khalid, J Ning… - Nature …, 2024 - nature.com
CDK4/6 inhibition in combination with endocrine therapy is the standard of care for estrogen
receptor (ER+) breast cancer, and although cytostasis is frequently observed, new treatment …
receptor (ER+) breast cancer, and although cytostasis is frequently observed, new treatment …
Targeting mTOR and glycolysis in HER2-positive breast cancer
RW Holloway, PA Marignani - Cancers, 2021 - mdpi.com
Simple Summary About one third of all breast cancers are classified as HER2-positive due
to high levels of the HER2 cell surface protein. Drugs that target HER2 have been mostly …
to high levels of the HER2 cell surface protein. Drugs that target HER2 have been mostly …
WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer
K Menck, S Heinrichs, D Wlochowitz, M Sitte… - Journal of Experimental …, 2021 - Springer
Background Breast cancer has been associated with activation of the WNT signaling
pathway, although no driver mutations in WNT genes have been found yet. Instead, a high …
pathway, although no driver mutations in WNT genes have been found yet. Instead, a high …
Organ-specificity of breast cancer metastasis
MK Ibragimova, MM Tsyganov, EA Kravtsova… - International Journal of …, 2023 - mdpi.com
Breast cancer (BC) remains one of the most common malignancies among women
worldwide. Breast cancer shows metastatic heterogeneity with priority to different organs …
worldwide. Breast cancer shows metastatic heterogeneity with priority to different organs …
PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer
C Wu, S Peng, PG Pilié, C Geng, S Park… - Molecular cancer …, 2021 - AACR
We analyzed the efficacy and mechanistic interactions of PARP inhibition (PARPi; olaparib)
and CDK4/6 inhibition (CDK4/6i; palbociclib or abemaciclib) combination therapy in …
and CDK4/6 inhibition (CDK4/6i; palbociclib or abemaciclib) combination therapy in …